Advertisement

Peripheral viral challenge exacerbates experimental autoimmune encephalomyelitis

  • Tiffany J. Petrisko
  • Gregory W. Konat
Short Communication
  • 2 Downloads

Abstract

Peripheral viral infections are potent triggers of exacerbation in multiple sclerosis (MS). Here, we used a preclinical model of MS, the experimental autoimmune encephalomyelitis (EAE) to corroborate this comorbidity in an experimental setting. EAE was induced by immunization of mice with MOG peptide, and paralysis was scored using a 5-point scale. At the onset of the chronic phase of the disease (Days 42–58 after MOG injection) the animals were divided into low responders (LR) and high responders (HR) with the mean score of 1.5 and 2.5, respectively. The acute phase response (APR) was induced by intraperitoneal injections of a viral mimetic, polyinosinic-polycytidylic acid (PIC). Two daily injections were performed on Days 42 and 44 (PIC42,44 challenge) and on Days 54, 55 and 56 (PIC54,55,56 challenge). PIC42,44 challenge had no effect of EAE disease, whereas PIC54,55,56 challenge rapidly increased paralysis but only in HR group. This exacerbation ultimately led to animal death by Day 58. These results demonstrate that antiviral APR is a potent exacerbator of EAE, and that this activity directly correlates with the severity of the disease. This in turn, indicates that antiviral APR might play a pivot role in linking peripheral viral infections with MS exacerbations.

Keywords

Polyinosinic-polycytidylic acid Experimental autoimmune encephalomyelitis Inflammatory mediators Viral challenge Acute phase response Multiple sclerosis 

Notes

Acknowledgements

This study was supported by a Pilot Grant from the National Multiple Sclerosis Society awarded to G.W.K.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

References

  1. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A (1993) Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 240:417–422CrossRefGoogle Scholar
  2. Borkosky SS, Whitley C, Kopp-Schneider A, zur HH, de Villiers EM (2012) Epstein-Barr virus stimulates torque teno virus replication: a possible relationship to multiple sclerosis. PLoS One 7:e32160CrossRefGoogle Scholar
  3. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meche FG, van Doorn PA, Hintzen RQ (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125:952–960CrossRefGoogle Scholar
  4. Cheng W, Chen G (2014) Chemokines and chemokine receptors in multiple sclerosis. Mediat Inflamm 2014:659206Google Scholar
  5. Clarner T, Janssen K, Nellessen L, Stangel M, Skripuletz T, Krauspe B, Hess FM, Denecke B, Beutner C, Linnartz-Gerlach B, Neumann H, Vallieres L, Amor S, Ohl K, Tenbrock K, Beyer C, Kipp M (2015) CXCL10 triggers early microglial activation in the cuprizone model. J Immunol 194:3400–3413CrossRefGoogle Scholar
  6. Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67:652–659CrossRefGoogle Scholar
  7. Dantzer R, Kelley KW (2007) Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 21:153–160CrossRefGoogle Scholar
  8. Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD (1998) Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 64:736–741CrossRefGoogle Scholar
  9. Guha-Thakurta N, Majde JA (1997) Early induction of proinflammatory cytokine and type I interferon mRNAs following Newcastle disease virus, poly [rI:rC], or low-dose LPS challenge of the mouse. J Interf Cytokine Res 17:197–204CrossRefGoogle Scholar
  10. Jacobs BL, Langland JO (1996) When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 219:339–349CrossRefGoogle Scholar
  11. Kakalacheva K, Munz C, Lunemann JD (2011) Viral triggers of multiple sclerosis. Biochim Biophys Acta 1812:132–140CrossRefGoogle Scholar
  12. Konat G (2016) Cerebral response to peripheral challenge with a viral mimetic. Neurochem Res 41:144–155CrossRefGoogle Scholar
  13. Libbey JE, Fujinami RS (2010) Potential triggers of MS. Results Probl Cell Differ 51:21–42CrossRefGoogle Scholar
  14. Liu MT, Keirstead HS, Lane TE (2001) Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol 167:4091–4097CrossRefGoogle Scholar
  15. Malmestrom C, Lycke J, Haghighi S, Andersen O, Carlsson L, Wadenvik H, Olsson B (2008) Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. J Neuroimmunol 196:159–165CrossRefGoogle Scholar
  16. Matullo CM, O'Regan KJ, Curtis M, Rall GF (2011) CNS recruitment of CD8+ T lymphocytes specific for a peripheral virus infection triggers neuropathogenesis during polymicrobial challenge. PLoS Pathog 7:e1002462CrossRefGoogle Scholar
  17. Michalovicz LT, Konat GW (2014) Peripherally restricted acute phase response to a viral mimic alters hippocampal gene expression. Metab Brain Dis 29:75–86CrossRefGoogle Scholar
  18. Michalovicz LT, Lally BE, Konat GW (2015) Peripheral challenge with a viral mimic upregulates expression of the complement genes in the hippocampus. J Neuroimmunol 285:137–142CrossRefGoogle Scholar
  19. Ngoi SM, Tovey MG, Vella AT (2008) Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. J Immunol 181:7670–7680CrossRefGoogle Scholar
  20. Nikfar S, Rahimi R, Abdollahi M (2010) A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. Clin Ther 32:1871–1888CrossRefGoogle Scholar
  21. Panitch HS (1994) Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36(Suppl):S25–S28CrossRefGoogle Scholar
  22. Peacock JW, Elsawa SF, Petty CC, Hickey WF, Bost KL (2003) Exacerbation of experimental autoimmune encephalomyelitis in rodents infected with murine gammaherpesvirus-68. Eur J Immunol 33:1849–1858CrossRefGoogle Scholar
  23. Petrisko T, Konat G (2017) Peripheral viral challenge triggers hippocampal production of inflammatory proteins. Metab Brain Dis 32:1249–1254CrossRefGoogle Scholar
  24. Pranzatelli MR (2018) Advances in biomarker-guided therapy for pediatric- and adult-onset Neuroinflammatory disorders: targeting chemokines/cytokines. Front Immunol 9:557CrossRefGoogle Scholar
  25. Rappert A, Bechmann I, Pivneva T, Mahlo J, Biber K, Nolte C, Kovac AD, Gerard C, Boddeke HW, Nitsch R, Kettenmann H (2004) CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci 24:8500–8509CrossRefGoogle Scholar
  26. Richard JF, Roy M, Audoy-Remus J, Tremblay P, Vallieres L (2011) Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6, ICAM1 and ITGalphaM. Brain Pathol 21:661–671CrossRefGoogle Scholar
  27. Sibley WA, Bamford CR, Clark K (1985) Clinical viral infections and multiple sclerosis. Lancet 1:1313–1315CrossRefGoogle Scholar
  28. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H (1998) Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 43:465–471CrossRefGoogle Scholar
  29. Traynor TR, Majde JA, Bohnet SG, Krueger JM (2004) Intratracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections. Life Sci 74:2563–2576CrossRefGoogle Scholar
  30. Verbeek R, van Dongen H, Wawrousek EF, Amor S, van Noort JM (2007) Induction of EAE by T cells specific for alpha B-crystallin depends on prior viral infection in the CNS. Int Immunol 19:277–285CrossRefGoogle Scholar
  31. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR (2006) Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80:5059–5064CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Departments of Biochemistry and Neuroscience, Rockefeller Neuroscience InstituteWest Virginia University School of MedicineMorgantownUSA

Personalised recommendations